TJ037

TJ037 is a small molecule drug candidate developed by Tuojie Biotech (拓界生物医药) that targets hypoxia-inducible factor (HIF). HIF is a transcription factor that plays a central role in the cellular response to low oxygen levels (hypoxia) by regulating genes involved in erythropoiesis, angiogenesis, and metabolism. While specific therapeutic indications for TJ037 are not explicitly detailed in the company's early-stage pipeline, HIF-targeting agents are commonly developed for the treatment of anemia (via HIF-prolyl hydroxylase inhibition) or various solid tumors (via HIF-1α or HIF-2α inhibition). TJ037 is part of Tuojie Biotech's small molecule research pipeline.